Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The ...
June 25 (Reuters) - Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $11.3 billion, the German science and healthcare firm said in a statement on Thursday. Shares of Bio-Techne rose ...
StockStory.org on MSN
Q1 earnings outperformers: Bio-Techne (NASDAQ:TECH) and the rest of the research tools & consumables stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and ...
View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.
Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...
An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results